Sionna Therapeutics (SION) CEO Cloonan received 218,050 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Michael Cloonan (President & CEO at Sionna Therapeutics Inc., SION) reported that they received 218,050 shares on Sep 17, 2026. After these transactions the filing shows 765,393 shares held directly.
- Reporting person
- Cloonan Michael
- Role
- President & CEO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Grant or award (A) | Common Stock1, 2 | +218,050 | - | - | 765,393 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Grant or award (A) | Non-Qualified Stock Option (right to buy)On 436,100 Common Stock3, 4, 5 | +436,100 | - | - | 436,100 direct |
| Sep 17, 2026 | Sale back to the company (D) | Non-Qualified Stock Option (right to buy)On 436,100 Common Stock4, 5 | -436,100 | - | - | 0 direct |
Holdings before and after
- Common Stock: 547,343 to 765,393 direct
Footnotes from the filing
- 1. Represents a grant of restricted stock units ( RSUs ). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
- 2. Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
- 3. The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the Repricing Date ). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the 2025 Plan )) or (iii) certain qualifying terminations of service.
- 4. Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- 5. This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Cloonan report in this SION Form 4?
Michael Cloonan (President & CEO at Sionna Therapeutics Inc., SION) reported that they received 218,050 shares on Sep 17, 2026. After these transactions the filing shows 765,393 shares held directly.
How many SION shares does Cloonan hold after this filing?
The filing shows 765,393 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for SION
Across the 20 sessions after earlier SION headlines, the stock closed higher 10 times and lower 10 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SION | SPY |
|---|---|---|---|
| Sep 15, 2026 | Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial | -16.7% | -0.5% |
| Aug 10, 2026 | Sionna Therapeutics downgraded by BTIG Researchand 7 other headlines that session | -91.2% | -0.0% |
| Aug 6, 2026 | Sionna Therapeutics Reports Second Quarter 2026 Financial Results | +4.8% | -0.2% |
| May 27, 2026 | Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences | +1.3% | -0.0% |
| May 13, 2026 | Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | +5.3% | +0.6% |
| May 5, 2026 | Wedbush initiated coverage on Sionna Therapeutics with a new price target | +1.3% | +0.8% |
Earlier insider filings at SION
- Jul 9, 2026Director Thompson Peter A. sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)
- Jul 9, 2026Director Orbimed Advisors Llc sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)
- Jul 7, 2026Chief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $446,862 worth of shares (10,250 units at $43.60) as part of a pre-agreed trading plan (SEC Form 4)
- Jul 2, 2026Director Thompson Peter A. sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)
- Jul 2, 2026Director Orbimed Advisors Llc sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)
Quantisnow market dataNASDAQ
SION
Sionna Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for SION
Full SION profile on Quantisnow Follow SION and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time